RedHill Biopharma’s Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

Written by Andreas Villaester on 13th January 2022. Posted in Client News.

• Previous
• Next